AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36083850 — intervention group
Group type: COMPARATOR
Intervention: MED
Number of subjects: 241
Study 32086350 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session attentional modification group
Number of subjects: 0
Study 32086350 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-session attentional modification group
Number of subjects: 0
Study 32086350 — intervention group
Group type: COMPARATOR
Intervention: 10-session placebo training group
Number of subjects: 0
Study 32086350 — intervention group
Group type: COMPARATOR
Intervention: 18-session placebo training group
Number of subjects: 0
Study 35067976 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 178
Study 35067976 — intervention group
Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 178
Study 34178863 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella vulgaris (CV) 900 mg/day
Number of subjects: 46
Study 34178863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) 3 sessions/week
Number of subjects: 46
Study 34178863 — intervention group
Group type: EXPERIMENTAL
Intervention: CV + HIIT
Number of subjects: 46
Study 34178863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 35012610 — intervention group
Group type: EXPERIMENTAL
Intervention: CD24Fc
Number of subjects: 22
Study 35012610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 32036492 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil/l-leucovorin (5-FU/l-LV)
Number of subjects: 101
Study 32036492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/l-leucovorin plus paclitaxel (FLTAX)
Number of subjects: 101
Study 32036492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/l-leucovin plus paclitaxel (FLTAX)
Number of subjects: 101
Study 36079720 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-lockdown dietary habits and lifestyle changes
Number of subjects: 59
Study 36079720 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with improved liver status
Number of subjects: 59
Study 32500276 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of brain diffusion-weighted imaging (DWI) using a scoring template.
Number of subjects: 75
Study 32500276 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative assessment of brain diffusion-weighted imaging (DWI).
Number of subjects: 75
Study 32667240 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective Narrative Therapy Groups (CNTG)
Number of subjects: 89
Study 32667240 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 89
Study 33413608 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-affected meridians (DAM) group
Number of subjects: 90
Study 33413608 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-affected meridians (NAM) group
Number of subjects: 90
Study 33413608 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA) group
Number of subjects: 90
Study 33413608 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 32538796 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP-HANA app
Number of subjects: 39
Study 32538796 — intervention group
Group type: COMPARATOR
Intervention: Attention control app
Number of subjects: 39
Study 34954935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle nursing of citric acid extracorporeal anticoagulation
Number of subjects: 94
Study 35085502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal faricimab 6.0 mg up to every 16 weeks
Number of subjects: 1329
Study 35085502 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks
Number of subjects: 1329
Study 33662176 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-monthly household visits
Number of subjects: 384
Study 32093766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrosigine (1.5g)
Number of subjects: 24
Study 32093766 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline Malate (8g)
Number of subjects: 24
Study 32093766 — intervention group
Group type: COMPARATOR
Intervention: Dextrose placebo (8g)
Number of subjects: 24
Study 36269401 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical face mask
Number of subjects: 84
Study 36269401 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2/K95 mask
Number of subjects: 84
Study 36269401 — intervention group
Group type: COMPARATOR
Intervention: No mask
Number of subjects: 84
Study 32865027 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth visits (weekly to biweekly)
Number of subjects: 29
Study 32865027 — intervention group
Group type: COMPARATOR
Intervention: Telephone calls (monthly)
Number of subjects: 29
Study 32631710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sienna XP (1 mL)
Number of subjects: 135
Study 32631710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sienna XP (1.5 mL)
Number of subjects: 135
Study 32631710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sienna XP (2 mL)
Number of subjects: 135
Study 32631710 — intervention group
Group type: COMPARATOR
Intervention: Radiotracer (Tc-99 m)
Number of subjects: 135
Study 35279628 — intervention group
Group type: EXPERIMENTAL
Intervention: AT+Vit D
Number of subjects: 38
Study 35279628 — intervention group
Group type: EXPERIMENTAL
Intervention: AT
Number of subjects: 38
Study 35279628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vit D
Number of subjects: 38
Study 35279628 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 36207990 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosacea patients with metabolic syndrome
Number of subjects: 79
Study 36207990 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosacea patients
Number of subjects: 79
Study 36207990 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 79
Study 35913759 — intervention group
Group type: EXPERIMENTAL
Intervention: ultrasound renal denervation (uRDN)
Number of subjects: 74
Study 35913759 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 74
Study 32911242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component pre-operative preparation program (including informative booklet, preoperative tour, educational DVD, therapeutic play intervention)
Number of subjects: 241
Study 32911242 — intervention group
Group type: COMPARATOR
Intervention: Informative booklet as routine information preparation
Number of subjects: 241
Study 35190375 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCP (atezolizumab + bevacizumab + carboplatin/paclitaxel)
Number of subjects: 920
Study 35190375 — intervention group
Group type: COMPARATOR
Intervention: BCP (bevacizumab + carboplatin/paclitaxel)
Number of subjects: 920
Study 35190375 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP (atezolizumab + carboplatin/paclitaxel)
Number of subjects: 920
Study 32600866 — intervention group
Group type: EXPERIMENTAL
Intervention: white ProRoot® MTA
Number of subjects: 30
Study 32600866 — intervention group
Group type: EXPERIMENTAL
Intervention: SavDen® MTA
Number of subjects: 30
Study 32600866 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 32600866 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (after internal bleaching)
Number of subjects: 30
Study 34776128 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial Release (MR)
Number of subjects: 65
Study 34776128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham
Number of subjects: 65
Study 34776128 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 32073330 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD pain in adolescence
Number of subjects: 2209
Study 32073330 — intervention group
Group type: COMPARATOR
Intervention: No previous history of TMD pain
Number of subjects: 2209
Study 32073330 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent TMD pain
Number of subjects: 2209
Study 32898357 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 120 kV tube voltage, CM dose 0.521 g I/kg; O: Mean attenuation 118.2 ± 10.0 HU.
Number of subjects: 256
Study 32898357 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 90 kV tube voltage, CM dose 0.521 g I/kg; O: Mean attenuation 141.0 ± 18.2 HU.
Number of subjects: 256
Study 32898357 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: 100 kV tube voltage, CM dose 0.417 g I/kg; O: Mean attenuation 117.6 ± 13.9 HU.
Number of subjects: 256
Study 32898357 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: 90 kV tube voltage, CM dose 0.365 g I/kg; O: Mean attenuation 117.3 ± 21.6 HU.
Number of subjects: 256
Study 33399241 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib added to endocrine therapy
Number of subjects: 0
Study 33399241 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 0
Study 33262194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored individual health trainer face-to-face and/or telephone support to reduce smoking and increase physical activity (PA)
Number of subjects: 0
Study 33262194 — intervention group
Group type: COMPARATOR
Intervention: Brief written/electronic advice to reduce or quit smoking (control)
Number of subjects: 0
Study 35134548 — intervention group
Group type: EXPERIMENTAL
Intervention: ECGI-guided driver ablation after pulmonary vein isolation (PVI)
Number of subjects: 40
Study 34527924 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin bath therapy (20 min, one session per day, for two weeks)
Number of subjects: 77
Study 34527924 — intervention group
Group type: COMPARATOR
Intervention: Fluidotherapy (same duration and frequency as paraffin bath therapy)
Number of subjects: 77
Study 32959458 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP (calcitonin gene-related peptide) intravenous infusion at 1.5μg/min over 20 minutes
Number of subjects: 30
Study 32959458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline) intravenous infusion over 20 minutes
Number of subjects: 30
Study 35899020 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine with 5 μg dexmedetomidine (group BD)
Number of subjects: 90
Study 35899020 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine with 10 mg meperidine (group BM)
Number of subjects: 90
Study 35899020 — intervention group
Group type: COMPARATOR
Intervention: 10 mg bupivacaine (group B)
Number of subjects: 90
Study 33183558 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic NO3- tablets (314 mM NO3-)
Number of subjects: 67
Study 33183558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NO3- free tablets)
Number of subjects: 67
Study 35926074 — intervention group
Group type: EXPERIMENTAL
Intervention: Curated social web application (interactive website) for COVID-19 vaccine confidence
Number of subjects: 592
Study 35926074 — intervention group
Group type: EXPERIMENTAL
Intervention: User experience testing (formal n=3, informal)
Number of subjects: 592
Study 35926074 — intervention group
Group type: EXPERIMENTAL
Intervention: Community building with 3 LTCW 'community ambassadors'
Number of subjects: 592
Study 33534044 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Q‐TAP block analgesia
Number of subjects: 68
Study 33534044 — intervention group
Group type: COMPARATOR
Intervention: TEA
Number of subjects: 68
Study 32382924 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort‐in™ injection system (CIS)
Number of subjects: 60
Study 32382924 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia (TA)
Number of subjects: 60
Study 32382924 — intervention group
Group type: COMPARATOR
Intervention: Patient preference for CIS
Number of subjects: 60
Study 35909329 — intervention group
Group type: EXPERIMENTAL
Intervention: EV 2 mg + DNG 2-3 mg (n=20)
Number of subjects: 59
Study 35909329 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 0.03 mg + DNG 2 mg (n=20)
Number of subjects: 59
Study 35909329 — intervention group
Group type: COMPARATOR
Intervention: DNG 2 mg (n=19)
Number of subjects: 59
Study 34548369 — intervention group
Group type: EXPERIMENTAL
Intervention: HED-Start intervention
Number of subjects: 148
Study 34548369 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148
Study 32142501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg once daily for 6 weeks
Number of subjects: 134
Study 32142501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 32142501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg once daily for 6 months
Number of subjects: 134
Study 34028342 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (negative alcohol-related event)
Number of subjects: 0
Study 34028342 — intervention group
Group type: COMPARATOR
Intervention: Control writing condition (first day of college)
Number of subjects: 0
Study 36250668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral surgery
Number of subjects: 142
Study 36250668 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 142
Study 32118508 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonophoretic application of a nanoemulsion incorporating glucosamine and chondroitin sulfate (NANO‐CG) associated with kinesiotherapy
Number of subjects: 0
Study 32118508 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34487086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour Oral Glucose Tolerance Test (OGTT)
Number of subjects: 43
Study 33143707 — intervention group
Group type: EXPERIMENTAL
Intervention: LLINs and Bti
Number of subjects: 11846
Study 33143707 — intervention group
Group type: EXPERIMENTAL
Intervention: LLINs and CEM
Number of subjects: 11846
Study 33143707 — intervention group
Group type: EXPERIMENTAL
Intervention: LLINs combined with Bti and CEM
Number of subjects: 11846
Study 33143707 — intervention group
Group type: COMPARATOR
Intervention: LLINs only
Number of subjects: 11846
Study 35360550 — intervention group
Group type: EXPERIMENTAL
Intervention: AI film reading system
Number of subjects: 104
Study 35360550 — intervention group
Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 104
Study 33934519 — intervention group
Group type: EXPERIMENTAL
Intervention: Durlobactam 4 g (supratherapeutic dose)
Number of subjects: 0
Study 33934519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33934519 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus moxifloxacin 400 mg (open-label)
Number of subjects: 0
Study 33313732 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chiropractic care (1 to 5 visits)
Number of subjects: 766
Study 33313732 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose chiropractic care (8 to 12 visits)
Number of subjects: 766
Study 33313732 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly chiropractic chronic pain management for 10 months
Number of subjects: 766
Study 33313732 — intervention group
Group type: COMPARATOR
Intervention: No scheduled chiropractic visits for 10 months
Number of subjects: 766
Study 34129088 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic complete mesocolic excision (CME)
Number of subjects: 372
Study 34129088 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic non-complete mesocolic excision (NCME)
Number of subjects: 372
Study 33832432 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized prescribing report from a medical regulatory authority (MRA)
Number of subjects: 272
Study 33832432 — intervention group
Group type: COMPARATOR
Intervention: Personal warning letter from the MRA
Number of subjects: 272
Study 33832432 — intervention group
Group type: COMPARATOR
Intervention: Personal phone call from an MRA pharmacist
Number of subjects: 272
Study 33832432 — intervention group
Group type: COMPARATOR
Intervention: Personal phone call from an MRA physician
Number of subjects: 272
Study 33832432 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 272
Study 34086481 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction neoadjuvant hormonal therapy (HT) with fulvestrant 500 mg (with or without goserelin)
Number of subjects: 258
Study 34086481 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg plus palbociclib
Number of subjects: 258
Study 34086481 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant 500 mg plus placebo
Number of subjects: 258
Study 32416026 — intervention group
Group type: EXPERIMENTAL
Intervention: HAF-Lidocaine (HA filler with 0.3% lidocaine)
Number of subjects: 62
Study 32416026 — intervention group
Group type: COMPARATOR
Intervention: HAF (HA filler without lidocaine)
Number of subjects: 62
Study 32416026 — intervention group
Group type: EXPERIMENTAL
Intervention: HAF-Lidocaine
Number of subjects: 62
Study 36454365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA intervention (at least 1 hour/week of supervised strenuous activity)
Number of subjects: 234
Study 36454365 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric dietary intervention mainly based on plant-foods
Number of subjects: 234
Study 36454365 — intervention group
Group type: COMPARATOR
Intervention: General recommendations on healthy dietary and PA patterns
Number of subjects: 234
Study 36454365 — intervention group
Group type: COMPARATOR
Intervention: Both dietary and PA interventions
Number of subjects: 234
Study 32712322 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofill void trial (group A)
Number of subjects: 82
Study 32712322 — intervention group
Group type: COMPARATOR
Intervention: Backfill void trial (group B)
Number of subjects: 82
Study 32058628 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on infant crying watched within 1 week of age during hospitalization at maternity wards.
Number of subjects: 2601
Study 32058628 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational video).
Number of subjects: 2601
Study 32058628 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on infant crying for young mothers (<25 years).
Number of subjects: 2601
Study 33821577 — intervention group
Group type: EXPERIMENTAL
Intervention: MNV3 group
Number of subjects: 83
Study 33821577 — intervention group
Group type: COMPARATOR
Intervention: MNV1 control group
Number of subjects: 83
Study 33821577 — intervention group
Group type: COMPARATOR
Intervention: MNV2 control group
Number of subjects: 83
Study 34956400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine nursing intervention
Number of subjects: 0
Study 34956400 — intervention group
Group type: COMPARATOR
Intervention: General nursing (Control)
Number of subjects: 0
Study 33128036 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal replacement combined with lifestyle intervention (INT)
Number of subjects: 463
Study 33128036 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention only (CON)
Number of subjects: 463
Study 35897310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum SNK12 (50 mg/day)
Number of subjects: 0
Study 35897310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum SNK12 (150 mg/day)
Number of subjects: 0
Study 35897310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 0
Study 33782036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (1.25-10 mg/d)
Number of subjects: 269
Study 33782036 — intervention group
Group type: COMPARATOR
Intervention: Non-RAS inhibition therapy
Number of subjects: 269
Study 33782036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 269
Study 32781939 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy plus transcutaneous electrical nerve stimulation
Number of subjects: 75
Study 32781939 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy plus interferential current
Number of subjects: 75
Study 32781939 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy plus Aussie current
Number of subjects: 75
Study 36342618 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX2660
Number of subjects: 267
Study 36342618 — intervention group
Group type: COMPARATOR
Intervention: Blinded Placebo
Number of subjects: 267
Study 34529065 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation at hospital admission
Number of subjects: 1702
Study 34529065 — intervention group
Group type: COMPARATOR
Intervention: Standard, physician-acquired medication history (Control)
Number of subjects: 1702
Study 33636242 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle patch plus 5% topical lidocaine
Number of subjects: 16
Study 33636242 — intervention group
Group type: COMPARATOR
Intervention: Patch without microneedles plus 5% topical lidocaine
Number of subjects: 16
Study 35535436 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VAR)
Number of subjects: 6653
Study 35535436 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (BUP)
Number of subjects: 6653
Study 35535436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 6653
Study 35535436 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 6653
Study 35535436 — intervention group
Group type: COMPARATOR
Intervention: All active treatments (VAR, BUP, NRT)
Number of subjects: 6653
Study 35535436 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric adverse events (NPSAEs)
Number of subjects: 6653
Study 34623418 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 7983
Study 34623418 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 7983
Study 34623418 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective parallel group
Number of subjects: 7983
Study 34623418 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers at Year 4
Number of subjects: 7983
Study 34623418 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers at Year 4
Number of subjects: 7983
Study 34623418 — intervention group
Group type: COMPARATOR
Intervention: Still smoking
Number of subjects: 7983
Study 34623418 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers who quit
Number of subjects: 7983
Study 32425111 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Na solution (112 mmol/L Na and 2% glucose)
Number of subjects: 123
Study 32425111 — intervention group
Group type: COMPARATOR
Intervention: Standard-Na solution (133 mmol/L Na and 1.5% glucose)
Number of subjects: 123